FENC (Fennec Pharmaceuticals Inc.) Stock Financials & Earnings

FENCFennec Pharmaceuticals Inc.

Mkt Cap$220M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$39M

Net Income (TTM)-$7M

EPS (TTM)-$0.24

Free Cash Flow (TTM)-$8M

Gross Margin93.1%

Op. Margin-12.0%

Net Margin-17.9%

FCF Margin-20.6%

P/S Ratio (TTM)5.7x

P/E Ratio (TTM)—

YoY Rev Growth-21.8%

Employees—

Earnings Reports

Next: Q4 2025 · Apr 1

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$2M	$1M	-$6M
Q1 23	$2M	$2M	-$5M
Q2 23	$3M	$3M	-$5M
Q3 23	$7M	$6M	-$1M
Q4 23	$10M	$9M	-$2M
Q1 24	$25M	$25M	$14M
Q2 24	$7M	$7M	-$5M
Q3 24	$7M	$6M	-$5M
Q4 24	$8M	$7M	-$934K
Q1 25	$9M	$8M	-$808K
Q2 25	$10M	$9M	-$3M
Q3 25	$12M	$12M	-$189K

Valuation

Operating Cash Flow

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$117K	$5M	$3M	—
Q1 23	$4K	$4M	$3M	—
Q2 23	$8K	—	—	$8M
Q3 23	$12K	$4M	$3M	—
Q4 23	$33K	—	—	$11M
Q1 24	$3K	$6M	$5M	—
Q2 24	$157K	$7M	$5M	—
Q3 24	$97K	$6M	$5M	—
Q4 24	$50K	$4M	$4M	—
Q1 25	$94K	$6M	$3M	—
Q2 25	$107K	$7M	$4M	—
Q3 25	$29K	$7M	$5M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$24M	$0	$24M
Q1 23	$18M	$0	$18M
Q2 23	$15M	$0	$15M
Q3 23	$12M	$0	$12M
Q4 23	$13M	$0	$13M
Q1 24	$51M	$0	$51M
Q2 24	$43M	$0	$43M
Q3 24	$40M	$0	$40M
Q4 24	$27M	$0	$27M
Q1 25	$23M	$0	$23M
Q2 25	$19M	$0	$19M
Q3 25	$22M	$0	$22M

Shares Outstanding

Revenue Per Employee

Revenue / Employee